Additionally, Jie-Hai Yu and others investigated the response to PD-1 inhibitors in colorectal cancer patients and found that patients with signet ring cell carcinoma and mucinous adenocarcinoma exhibited weaker responses to immunotherapy, thereby indicating a higher risk of poor outcomes and prognosis [47]. The gene discussed is PDCD1; the disease is colorectal cancer.